Prevalence and Characteristics of Overactive Bladder in Women in a Primary Care Setting

Cheung, Wellman; Harel, Miriam; Abulafia, Ovadia; Khan, Nadia; Choi, Karmina K; Bluth, Martin H.; Vincent, M.

doi:10.1016/s0022-5347(09)61590-1

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overactive bladder syndrome (OAB) is a common condition affecting up to 43% of women in the United States. 1,2 For many patients, symptoms of OAB include a loss of self-esteem, restriction of activities and psychological distress. 3–7 The American Urological Association and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction recommends patients try medication and behavioral modification before proceeding to third-line OAB treatments which include percutaneous tibial nerve stimulation (PTNS), onabotulinumtoxinA and sacral neuromodulation (SNM).…”

mentioning

confidence: 99%

Patient Perceptions Impact Progression to Third-Line Therapy for Treatment of Overactive Bladder

et al. 2021

View full text Add to dashboard Cite

Purpose: We aimed to understand the reasons patients choose to pursue thirdline overactive bladder (OAB) therapy. Materials and Methods: We conducted a mixed methods study that included patient interviews and survey data. Eligible patients were diagnosed by symptoms, had tried behavioral modifications, and OAB medications enrolled from October 2018 to August 2019. In addition to interviews, patients completed 4 surveys: the Pelvic Floor Distress Inventory, Overactive Bladder Questionnaire Short Form, Life Orientation TestdRevised, and a patient confidence in the health care system survey. Qualitative interview data were analyzed thematically. Logistic regression and chi-square analysis was used to analyze survey data. Results: A total of 69 patients were consented, 4 withdrew, and 51 completed both interview and survey data. Overall 55% of patients were Caucasian, 45% were African American, and their average age was 71 (SD[10.4); 75% intended to pursue third-line OAB therapy and 31 (61%) expressed interest in a specific third-line therapy. Major interview themes included a desire for a better quality of life, embarrassment with accidents, and problems with medication. Themes leading patients away from third-line OAB treatment included concern about invasiveness and side effects of treatments, and restrictions to accessing care. Conclusions: Most patients desired to progress to third-line OAB therapy, were motivated by embarrassment, but were concerned about treatment side effects. We found that economic burden of OAB treatment is associated with patient interest in and decision to receive third-line therapies to include onabotuli-numtoxinA and percutaneous tibial nerve stimulation. Improved quality of life, medication frustration, and concerns about side effects of further therapy are themes patients identified when patients considered third-line overactive bladder therapy.

show abstract

mentioning

confidence: 99%

Patient Perceptions Impact Progression to Third-Line Therapy for Treatment of Overactive Bladder

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Further, the psychosocial aspects of such diseases can often affect quality of life for female patients and promote reclusive behavior and/or depression for fear of embarrassment. 2,[5][6][7][8] The economic burden on the health-care system is also a concern in light of the aging population. 6,7 Options for disease management can range from therapy to surgical intervention and often vary according to disease presentation and urological comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood mononuclear cell gene array profiles in female patients with involuntary bladder contractions

Cheung¹,

Bluth²,

Khan³

et al. 2011

AGG

Self Cite

View full text Add to dashboard Cite

“…The Turkish-validated International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and OAB-V8 discriminated patients according to disease severity at baseline and after treatment to assess treatment efficacy. Positive OAB-V8 scores were categorized in two groups according to symptom severity: 8-13 and ≥ 14 [9]. An ICIQ-SF score of 8 was the cutoff value to define bothersome urinary incontinence, and based on a previous study in Turkish women, patients were classified into two severity levels, < 8 and ≥ 8 [10].…”

Section: Methodsmentioning

confidence: 99%

Data do not support the use of elevated urinary nerve growth factor and fractalkine levels as diagnostic and prognostic biomarkers for women with overactive bladder

Başok

Pelit

et al. 2015

Bladder

View full text Add to dashboard Cite

OBJECTIVE: This study investigated urinary nerve growth factor (NGF) and fractalkine levels in women with overactive bladder (OAB), as well as diagnostic and/or prognostic roles, and correlation of these urinary biomarkers with symptom severity of patients. MATERIALS AND METHODS:Twenty-seven women with OAB and 26 healthy subjects were enrolled. Patients were diagnosed with OAB based on symptoms, a 3-day voiding diary and a validated Turkish version of the Overactive Bladder-Validated 8 (OAB-V8) questionnaire. The urinary baseline levels of NGF and fractalkine were compared between OAB patients and control group. The Turkish-validated International Consultation on Incontinence Questionnaire Short Form and OAB-V8 used to categorize patients according to disease severity to assess treatment efficacy. Further urinary NGF and fractalkine levels were compared before and after antimuscarinic treatment. RESULTS:Urinary NGF/creatinine (Cr) and fractalkine/Cr were significantly elevated in OAB patients (0.40 ± 0.40 ng/ mg and 4.63 ± 4.36 ng/mg, respectively) compared to healthy subjects (0.14 ± 0.08 ng/mg and 2.00 ± 1.29 ng/mg, P = 0.002 and P = 0.005, respectively). Sensitivity and specificity were 85.2%, 65.4% for NGF, and 74.1%, 65.4% for fractalkine, respectively. No significant differences in NGF/Cr and fractalkine/Cr compared to baseline (P = 0.063 and 0.162, respectively) were observed after trospium chloride treatment in OAB patients. NGF/Cr and fractalkine/Cr exhibited no correlations with symptom severity levels. CONCLUSIONS:Increased urinary NGF/Cr and fractalkine/Cr levels were found in OAB women. However, the sensitivity and specificity were not sufficient for diagnostic use. NGF and fractalkine levels were decreased after treatment insignificantly, and there was no correlation with symptom severity; therefore their prognostic worth was limited.

show abstract

Prevalence and Characteristics of Overactive Bladder in Women in a Primary Care Setting

Cited by 6 publications

References 0 publications

Patient Perceptions Impact Progression to Third-Line Therapy for Treatment of Overactive Bladder

Patient Perceptions Impact Progression to Third-Line Therapy for Treatment of Overactive Bladder

Peripheral blood mononuclear cell gene array profiles in female patients with involuntary bladder contractions

Data do not support the use of elevated urinary nerve growth factor and fractalkine levels as diagnostic and prognostic biomarkers for women with overactive bladder

Contact Info

Product

Resources

About